Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

← catalyst calendar

NCT06101134 · results posted

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100actual
Sites
31
Countries
Chile, Greece, Italy +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-11-06actualWhen the study began enrolling
Primary completion2025-04-10actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-02-26estimatedThe whole study's end, after follow-up
First posted2023-10-26actualWhen this record first appeared on the registry
Results posted2026-04-09actualWhen the sponsor posted results to the registry
Record updated2026-08-19actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Melanoma

Interventions

  • Drug: relatlimab+nivolumab — also filed as BMS-986213, Opdualag
  • Drug: relatlimab+nivolumab+rHuPH20
  • Drug: nivolumab — also filed as BMS-936558, Opdivo
  • Drug: nivolumab+rHuPH20 — also filed as BMS-986298

Primary outcome

what the primary-completion date above is the date OF
Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose
measured Cycle 4 Day 1 (each cycle consist of 4 weeks)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol and Statistical Analysis Planposted 2024-05-24 · 6.4 MB · Prot_SAP_000.pdf

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed